Director of the Gamaleya Gintsburg Center: a new drug in the second half of spring
Alexander Gunzburg. Photo: Mikhail Klimentyev / Kremlin Pool / Global Look Press
Clinical trials of a drug against coronavirus based on monoclonal antibodies have begun at the Gamaleya Center. This was told by the director of the center Alexander Gintsburg, reports TASS.
As Gunzburg explained, the first and second phases of the trial will take three and a half to four months. “I hope we will see this drug in the second half of spring,” he added. The specialist stressed that the effectiveness of the drug is already known from Western analogues.
Last December, the Gamaleya Center received a patent for a coronavirus treatment that can trigger an immune response in babies over one month old. According to the service, this remedy will affect humoral and cellular immunity.
